Featured News

Today, the U.S. Food and Drug Administration issued a final rule for gluten-free labeling compliance requirements for fermented and hydrolyzed foods.

I want to share with you an update of our work in Washington, DC with Congress and NIH to accelerate research for diagnostics, treatments, and a cure for celiac disease.

Thanks to your generous support, we are deploying iCureCeliac and iQualifyCeliac, as well as other assets unique to the Foundation, to further celiac disease drug development.

CDF has been approved for a $100,000 funding award through the Eugene Washington PCORI Engagement Awards program. The funds will support the community convening of patient advocates, researchers, and other key stakeholders to create a roadmap for patient advocate engagement in research.

On Friday, I joined three of the leading celiac disease researchers in the world to present to the NIH’s Autoimmune Disease Coordinating Committee (ADCC) the findings from the CDF-sponsored First SSCD Consensus Workshop: Research Opportunities in Celiac Disease 2020.

The lecture "Non-celiac gluten sensitivity: what is the evidence?", hosted by Celiac Disease Center at Columbia University, will be held at the Faculty House at Columbia University on January 15, 2020. The lecture will be presented by the Celiac Disease Foundation's Young Investigator Award recipient, Benjamin Lebwohl, MD.

Researchers at the Mucosal Immunology and Biology Research Center (MIBRC) at Massachusetts General Hospital, led by Stefania Seger and CDF Medical Advisory Board member Alessio Fasano, have created 3-D, miniature models of the intestines in order to research celiac disease.

ImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe and effective in reducing the symptoms of seropositive celiac disease patients on a gluten-free diet. A significant improvement in both symptom severity and quality of…

Researchers at the Beth Israel Deaconess Medical Center, including Celiac Disease Foundation Medical Advisory Board Member Dan Leffler, conducted a study to determine the effects of the gluten-free diet (GFD) on weight changes in celiac patients after diagnosis. The authors note that while weight gain would be welcome and expected in initially underweight patients, similar…

We put together a list of some of the most common perceived barriers to participating in clinical trials, and how to overcome them.